Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: A 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial

被引：43

作者：

Gavrila, A

Hsu, W

Tsiodras, S

Doweiko, J

Gautam, S

Martin, L

Moses, AC

Karchmer, AW

Mantzoros, CS

机构：

[1] Beth Israel Deaconess Med Ctr, Div Endocrinol & Metab, Boston, MA 02215 USA

[2] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA

[3] Beth Israel Deaconess Med Ctr, Div Translat Res, Dept Med, Boston, MA 02215 USA

[4] Joslin Diabet Ctr, Boston, MA 02215 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 40卷 / 05期

关键词：

D O I：

10.1086/427697

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We designed a factorial, randomized, double-blinded, 2 x 2 placebo-controlled trial to evaluate the effects of treatment with pioglitazone and/or fenofibrate in patients with highly active antiretroviral therapy (HAART)-induced metabolic syndrome. We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period.

引用

收藏

页码：745 / 749

页数：5

相关论文

共 12 条

[1] Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy [J].

Calmy, A ;

Hirschel, B ;

Hans, D ;

Karsegard, VL ;

Meier, CA .

AIDS, 2003, 17 (05) :770-772

[2] Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART [J].

Calza, L ;

Manfredi, R ;

Chiodo, F .

AIDS, 2003, 17 (06) :851-859

[3]

Caramelli B, 2001, Braz J Infect Dis, V5, P332

[4] No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial [J].

Carr, A ;

Workman, C ;

Carey, D ;

Rogers, G ;

Martin, A ;

Baker, D ;

Wand, H ;

Law, M ;

Samaras, K ;

Emery, S ;

Cooper, DA .

LANCET, 2004, 363 (9407) :429-438

[5] Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors [J].

de Luis, DA ;

Bachiller, P ;

Aller, R .

NUTRITION, 2001, 17 (05) :414-415

[6] Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity [J].

Dobrian, AD ;

Schriver, SD ;

Khraibi, AA ;

Prewitt, RL .

HYPERTENSION, 2004, 43 (01) :48-56

[7] Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot study [J].

Gelato, MC ;

Mynarcik, DC ;

Quick, JL ;

Steigbigel, RT ;

Fuhrer, J ;

Brathwaite, CEM ;

Brebbia, JS ;

Wax, MR ;

McNurlan, MA .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (02) :163-170

[8] Metabolic effects of rosiglitazone in HIV lipodystrophy - A randomized, controlled trial [J].

Hadigan, C ;

Yawetz, S ;

Thomas, A ;

Havers, F ;

Sax, PE ;

Grinspoon, S .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (10) :786-794

[9] Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: Clinical presentation, pathophysiology, and therapeutic strategies [J].

Leow, MKS ;

Addy, CL ;

Mantzoros, CS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :1961-1976

[10] Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy [J].

Palacios, R ;

Santos, J ;

González, M ;

Ruiz, J ;

Valdivielso, T ;

Márquez, M ;

González-Santos, P .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (02) :251-253